Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine.
Shulman RM, Weinberg DS, Ross EA, Ruth K, Rall GF, Olszanski AJ, Helstrom J, Hall MJ, Judd J, Chen DYT, Uzzo RG, Dougherty TP, Williams R, Geynisman DM, Fang CY, Fisher RI, Strother M, Huelsmann E, Adige S, Whooley PD, Zarrabi K, Gupta B, Iyer P, McShane M, Yankey H, Lee CT, Burbure N, Laderman LE, Giurintano J, Reiss S, Horwitz EM. Shulman RM, et al. Among authors: olszanski aj. J Natl Compr Canc Netw. 2022 Feb;20(2):160-166. doi: 10.6004/jnccn.2021.7113. J Natl Compr Canc Netw. 2022. PMID: 35130494 Free PMC article.
Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment.
Wagner J, Kline CL, Zhou L, Campbell KS, MacFarlane AW, Olszanski AJ, Cai KQ, Hensley HH, Ross EA, Ralff MD, Zloza A, Chesson CB, Newman JH, Kaufman H, Bertino J, Stein M, El-Deiry WS. Wagner J, et al. Among authors: olszanski aj. J Clin Invest. 2018 Jun 1;128(6):2325-2338. doi: 10.1172/JCI96711. Epub 2018 Apr 30. J Clin Invest. 2018. PMID: 29533922 Free PMC article.
Principles of immunotherapy.
Olszanski AJ. Olszanski AJ. J Natl Compr Canc Netw. 2015 May;13(5 Suppl):670-2. doi: 10.6004/jnccn.2015.0199. J Natl Compr Canc Netw. 2015. PMID: 25995426
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Kaffenberger BH, Lunning M, McGettigan S, McPherson J, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Pennell N, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Weight RM, Johnson-Chilla A, Zuccarino-Catania G, Engh A. Thompson JA, et al. Among authors: olszanski aj. J Natl Compr Canc Netw. 2020 Mar;18(3):230-241. doi: 10.6004/jnccn.2020.0012. J Natl Compr Canc Netw. 2020. PMID: 32135517
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, Bhatia S, Budde LE, Chokshi S, Davies M, Elshoury A, Gesthalter Y, Hegde A, Jain M, Kaffenberger BH, Lechner MG, Li T, Marr A, McGettigan S, McPherson J, Medina T, Mohindra NA, Olszanski AJ, Oluwole O, Patel SP, Patil P, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Zaha VG, Lyons M, Dwyer M, Hang L. Thompson JA, et al. Among authors: olszanski aj. J Natl Compr Canc Netw. 2022 Apr;20(4):387-405. doi: 10.6004/jnccn.2022.0020. J Natl Compr Canc Netw. 2022. PMID: 35390769 Review.
93 results